Adverum Biotechnologies Stock Z Score
| ADVM Stock | USD 6.45 0.29 4.71% |
Adverum |
Adverum Biotechnologies Company Z Score Analysis
Adverum Biotechnologies' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Adverum Biotechnologies has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Adverum Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adverum Biotechnologies' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adverum Biotechnologies could also be used in its relative valuation, which is a method of valuing Adverum Biotechnologies by comparing valuation metrics of similar companies.Adverum Biotechnologies is currently under evaluation in z score category among its peers.
Adverum Fundamentals
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (29.22) % | ||||
| Current Valuation | 48.17 M | ||||
| Shares Outstanding | 20.8 M | ||||
| Shares Owned By Insiders | 11.67 % | ||||
| Shares Owned By Institutions | 79.15 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Earning | (2.10) X | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 128.14 X | ||||
| Revenue | 3.6 M | ||||
| Gross Profit | (81.68 M) | ||||
| EBITDA | (112.6 M) | ||||
| Net Income | (117.17 M) | ||||
| Cash And Equivalents | 235.84 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 75.04 M | ||||
| Debt To Equity | 0.43 % | ||||
| Current Ratio | 8.03 X | ||||
| Book Value Per Share | 6.93 X | ||||
| Cash Flow From Operations | (90.9 M) | ||||
| Short Ratio | 9.27 X | ||||
| Earnings Per Share | (5.95) X | ||||
| Target Price | 30.29 | ||||
| Number Of Employees | 121 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 128.14 M | ||||
| Total Asset | 173.01 M | ||||
| Retained Earnings | (919.78 M) | ||||
| Working Capital | 77.86 M | ||||
| Current Asset | 260.99 M | ||||
| Current Liabilities | 6.57 M | ||||
| Net Asset | 173.01 M |
About Adverum Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adverum Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adverum Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adverum Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Adverum Biotechnologies Piotroski F Score and Adverum Biotechnologies Valuation analysis. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.